The RNA Transcript, March 1, 2021 |
|
TODAY - March 1, "Data Blitz" Submission deadline
to our 5th Annual RNA Symposium - click here to submit
|
|
This Wednesday, March 3, 4:00–5:00 pm EST
This event is re-scheduled from Feb. 10, 2021. Non-scientists are welcome.
|
|
“A timely confluence: the backstory of Moderna’s COVID-19 vaccine”
Melissa Moore, Ph.D., Chief Scientific Officer at Moderna Therapeutics
|
|
February 28 was Rare Disease Day
Altogether, over 6,800 rare diseases affect an estimated 25 million to 30 million Americans. These patients who suffer from genetic mutations that often occur within the same family, are still nowadays left with few, if any, therapeutic options. However, RNA on-going discoveries and the development of new technology and tools such as CRISPR offer new hopes for rare disease therapy and prevention.
Studying rare diseases can also lead to remarkable insights into common diseases. For example, the understanding and subsequent treatment for osteoporosis and osteoarthritis have benefited from three rare disease studies. The development of a cholesterol-lowering drug, one of the most frequently prescribed medicines in the developed world and which has saved countless lives, was initiated through the study of familial hypercholesterolemia, a disease that affects one in 300,000 people.
|
|
Several members of the University of Michigan (U-M) Center for RNA Biomedicine are studying such diseases. On the occasion of Rare Disease Day, February 28, we asked Anthony Antonellis, Ph.D., Chair of the Department of Human Genetics, Medical School, and member of the Center for RNA Biomedicine, about his research and collaborations.
|
|
Tuesday, March 2, 3:00 pm EST | Harvard Medical School Initiative for RNA Medicine Seminar
“Protein-RNA interactions in vitro predict in vivo binding and regulation”
Professor of Biology, Director of Computational and Systems Biology PhD Program, MIT
|
|
Wednesday, March 3, 10:00 am EST | U-M Cellular & Molecular Biology, Medical School
Dissertation defense: "Targeting the KRAS and EGFR Oncogenes"
Jessica Waninger, Ph.D. Candidate
Faculty: Arul M Chinnaiyan, M.D., Ph.D.
|
|
Wednesday–Thursday, March 3–4, 1:00–3:30 pm EST | The University at Albany, RNA Institute Mini Symposium
Virtual Symposium featuring Nobel Laureate, Michael Rosbash, and presentations from Postdoctoral and Graduate Students
|
|
Sponsored by the
University of Michigan Biosciences and Lexogen
|
|
|
Our members' publications are available through Altmetric. Five queries are currently available: "RNA," "microRNA," "Transcriptome," "Translation," and "Molecule." Please make sure to have at least one of these key words in your title or abstract. Below is a recent highlight.
|
|
What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. Juhlin, C.C., Bertherat, J., Giordano, T.J. et al. Endocr Pathol (2021). https://doi.org/10.1007/s12022-021-09667-0
Abstract:
We herein review the histological, genetic, and epigenetic landscapes of benign and malignant adrenal cortical neoplasia from a modern surgical endocrine pathology perspective and highlight key mechanisms of value for diagnostic and prognostic purposes.
|
|
Together, with your support for RNA research,
we can revolutionize medicine and help cure millions of people.
|
|
|
|
SHARE YOUR NEWS AND COMMENTS
|
|
|
|
|
|
|
